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Despite the widespread nature of HTLV-II in New World populations and intravenous drug users, the enzymatic activities
of the pol genes have not been reported. To ascertain the activity of the HTLV-IIG12 integrase (IN), the coding region was
isolated and the encoded protein was purified, using nickel-affinity chromatography, to greater than 90% homogeneity.
HTLV-IIG12 IN proved active on HTLV-IIG12 and HIV-1 integration and disintegration substrates. Distinct differences in require-
ments for enzyme concentration for 3*-processing, strand-transfer, and disintegration reactions were observed. Catalysis
of integration reactions occurred in the presence of either Mn2/ or Mg2/, although strand-transfer activity preferred Mn2/.
In comparison, HTLV-IIG12 IN catalyzed disintegration reactions with almost 10-fold less protein, was not selective for Mn2/
or Mg2/, and tolerated higher NaCl concentrations than integration. HTLV-IIG12 IN was unable to catalyze the ‘‘splicing’’
reaction, which suggests that this may not be an activity ubiquitous to all retroviral integrases. q 1996 Academic Press, Inc.
INTRODUCTION Integration provides an essential step in the retroviral
life cycle by inserting a DNA copy of the viral genomeHuman T-cell leukemia virus type IIG12 (HTLV-IIG12 )
3
into the host genomic DNA (Brown, 1990; Grandgenettwas originally isolated from an asymptomatic Guaymi
and Mumm, 1990; Varmus and Swanstrom, 1984). ThisIndian in Panama (Pardi et al., 1993). This population
event comprises two enzymatic steps, 3*-processing andshows an 8 to 9% seropositive reaction for HTLV. In con-
strand transfer, mediated by the viral-encoded enzymetrast to human T-cell leukemia virus type I, little is known
integrase (IN). Equally essential for this process are theabout the natural history of infection, pathogenicity, and
long terminal repeat sequences (LTR) that flank the twoencoded enzyme activities of HTLV-II. Originally isolated
ends of the linear reverse-transcribed retroviral DNA. 3*-from a patient with an atypical hairy T-cell leukemia
Processing removes nucleotides from each 3* end of the(Chen et al., 1983; Kalyanaraman et al., 1982), subse-
viral LTR, leaving the conserved CA recessed at the 3*quent screening found HTLV-II endemic to fairly ‘‘closed’’
end (Brown et al., 1989; Katzman et al., 1989; Roth et al.,societies such as the Amerindian populations of Florida
1989). Strand transfer covalently joins the 3* recessed(Levine et al., 1993) and New Mexico (Hjelle et al., 1991)
end of each processed LTR to the target DNA by a one-and the native Indians of Panama (Pardi et al., 1993). In
step transesterification reaction (Engelman et al., 1991).studies of the Navajo and Pueblo Indians of New Mexico,
In the presence of a substrate that mimics an integrationHTLV-II was not correlated with an increased risk for
intermediate, IN mediates a reverse reaction of integra-hairy cell leukemia, chronic leukemia, or mycosis fun-
tion, disintegration (Chow et al., 1992). All of these cata-goides in a population with a fairly high rate of HTLV-II
lytic activities are readily reconstituted in vitro using DNAinfection (1.0 to 1.6%). A significantly increasing number
substrates and require only IN and the substrate in theof HIV-1-seropositive intravenous drug abusers (IVDAs)
presence of a metal ion (Craigie et al., 1990; Katzman etare coinfected with HTLV-II (de-The and Bomford, 1993;
al., 1989).Hall et al., 1992; Lee et al., 1989). In these coinfected
This paper presents the first report of the purificationpopulations, the presence of HTLV-II may affect progres-
and the associated integration and disintegration activi-sion of HIV-1 disease (Kaplan et al., 1991; Page et al.,
ties of HTLV-IIG12 IN. Yield and stability of the HTLV-IIG121990; Wang et al., 1993).
IN were excellent, and HTLV-IIG12 IN showed efficient
integration activity in the presence of either Mn2/ or1 Current address: Neurosciences Training Program, University of
Mg2/. One enzymatic activity, ‘‘splicing,’’ observed withColorado Health Science Center, Denver, CO 80262.
2 To whom correspondence and reprint requests should be ad- other integrases such as HIV-1 and M-MuLV, was lack-
dressed. Fax: (505) 646-2649; E-mail: cjonsson@nmsu.edu. ing. The properties of several INs are known, yet limited
3 Abbreviations used: IN, integrase; HTLV-II, human T-cell leukemia information exists on the specific activity for each reac-virus type II; HIV-1, human immunodeficiency virus type 1; M-MuLV,
tion. We present results that show the optimum concen-Moloney murine leukemia virus; IVDAs, intravenous drug abusers; nt,
nucleotide(s); AMV, avian myeloblastosis virus. trations of HTLV-IIG12 IN enzyme required for 3*-pro-
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cessing, strand transfer, and disintegration activities dif- supernatant was purified on a 1-ml nickel nitrilotriacetate
agarose affinity column facilitated by the hexahistidinefer significantly.
tag (Ni2/-NTA; Qiagen, Chatsworth, CA). The eluted IN
protein was collected in 10 1-ml fractions and samplesMATERIALS AND METHODS
were quantitated by Bradford’s assay (Bradford, 1976)
Materials using Bio-Rad Reagent (Madison, WI). Protein elution
was characterized by a tailing off from the column.Oligonucleotide primers were purchased from Anagen
Column fractions were pooled and adjusted with BufferTechnologies (Palo Alto, CA), restriction enzymes from
A to five different concentrations of protein: 0.8, 2.5, 5.0,Gibco BRL (Gaithersburg, MD) and New England Biolabs
10, and 16 mg/ml. Fractions were placed in 1 liter of 3 M(Beverly, MA), Vent polymerase from New England Bio-
urea in Buffer B [1 M NaCl, 40 mM HEPES, pH 7.4, 2 mMlabs, T4 DNA polynucleotide kinase from Gibco BRL, and
EDTA, 10 mM b-mercaptoethanol (BME), 0.4% NP-40,crude [g-32P]ATP from ICN (Irvine, CA). Chemicals were
10% glycerol]. The protein fractions were refolded by dial-purchased from Sigma Chemical Co. (St. Louis, MO).
ysis through a step-wise dilution of urea from 3 to 0 M
in Buffer B. The denaturant was diluted with fresh BufferCloning of the HTLV-IIG12 integrase gene
B by 1 M urea every 24 hr over a 3-day period. A final
The full-length HTLV-IIG12 genome was a gift from Dr. dialysis of the fractions was conducted in Buffer C [200
Diane Pardi (Center for Disease Control, Atlanta, GA) mM NaCl, 40 mM HEPES, pH 7.4, 0.1 mM EDTA, 1 mM
(Pardi et al., 1993). The coding region for HTLV-IIG12 IN DTT, 0.4% NP-40, 10% glycerol] for a further 36 hr, which
was amplified by polymerase chain reaction (PCR) using included one change of the buffer after 24 hr. In the final
Vent DNA polymerase starting at position 4290 at the 5* dialysis step, a protein precipitate was formed which
end of the proviral genome. The primers, P14227-1193 was greater than 95% IN. The precipitated protein was
(5* AAGCTTCATATGCTTATCCCCCTGACGCCCC) and centrifuged at 12,000 g for 5 min and resuspended in the
P20283-0294 (5* CTCGAGCCCATGGTGTTGG), intro- final dialysis Buffer D [40 mM HEPES, pH 7.4, 500 mM
duced NdeI and XhoI restriction sites (underlined) at the NaCl, 0.1 mM EDTA, 1 mM DTT, 0.4% NP-40, 10% glyc-
5* and 3* ends, respectively, of the encoded HTLV-IIG12 erol], which completely resuspended the protein pre-
IN DNA sequence. The 920-bp PCR-amplified DNA was cipitate. The fractions were frozen in dry ice and stored
digested with NdeI and XhoI, gel isolated, and glass- at 0807.
fines purified (Vogelstein and Gillespie, 1979). The iso-
lated gene was cloned into the NdeI–XhoI restricted en- SDS–PAGE, polyclonal antibody production, and
zyme sites of pET22B (Novagen, Madison, WI) to gener- Western analysis
ate the HTLV-IIG12 IN expression vector pET22INHIIg.
Fifteen percent SDS–polyacrylamide gel electrophore-Ligation of the IN gene into the XhoI site adds the DNA
sis was used to analyze column fractions and confirmsequence encoding a hexahistidine tag to the 3* end.
protein size. Polyclonal antibodies to the HTLV-IIG12 INExpression of the HTLV-IIG12 IN protein is directly under
were generated by injecting the highly purified proteinthe control of the T7/lac promoter, thus facilitating protein
into rabbits. TiterMax (Vaxel Inc., Norcross, GA) was usedexpression through addition of isopropyl-1-thio-b-D-ga-
as adjuvant in a 1:1 ratio with the antigen (used as perlactopyranoside (IPTG) to the bacterial culture (Studier
directions of manufacturer). One milliliter of the purifiedand Moffat, 1986).
and active HTLV-IIG12 IN protein (1 mg/ml) was combined
Protein expression and purification with 1.0 ml of the TiterMax adjuvant and given as four
40-ml subcutaneous injections. After 14 days, 10 ml of
HTLV-IIG12 IN protein was purified from pET22INHIIg- the rabbit blood was collected and centrifuged, and the
transformed Escherichia coli BL21(DE3) (Novagen) by a
sera were frozen at 0807. Reactivity of the antibody was
modification of the protocol described by Jonsson et al.
ascertained by Western analysis as described earlier
(1993). Briefly, BL21(DE3) clones harboring the pETIN-
(Jonsson et al., 1993). HIV-1 IN was expressed from pJL10
HIIg construct were cultured in 1 liter of 21 YT media
in BL21(DE3) cells similar to the method described for
containing 200 mg of ampicillin per milliliter. Protein ex-
HTLV-IIG12 IN (NIH Research and Reference Reagent Pro-pression was induced by adding IPTG to a final concen-
gram).
tration of 0.4 mM during early log phase (0.6 A600 units).
Cells were harvested after 2.5 hr of further incubation Integration and disintegration assays
and solubilized in 40 ml of Buffer A [6 M guanidine HCl,
0.5 M NaCl, 20 mM Tris, pH 8.0, 0.1 mM EDTA, 1 mM Enzymatic activities of the purified HTLV-IIG12 IN,
namely, 3*-processing, strand transfer, and disintegrationdithiothreitol (DTT), 0.4% Nonidet-P40 (NP-40)] with mild
agitation at room temperature for 1 hr. The insoluble were assayed using identical buffer conditions with stan-
dard in vitro radioactive-based assays (Jonsson et al.,fraction was removed by centrifuging the suspension for
30 min at 16,000 g. Solubilized protein from the clear 1993). Oligonucleotide sequences corresponding to the
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terminal 20 bp from U5 and U3 LTRs of the HTLV-IIG12 gration activities (data not shown). The protein fraction
refolded at a concentration of 5 mg/ml exhibited greatestviral DNA were used as substrates (Fig. 2B). All assays
were performed in a 15-ml final reaction volume con- enzymatic activity. Refolding at lower concentrations re-
tained partial activity, while fractions refolded at highertaining 25 mM MOPS (pH 7.2), 10 mM BME, 10% glycerol,
0.75 mM 3-[(3-cholamidopropyl)dimethylammonio]-1-pro- protein concentrations had no activity. A slight increase
in the purity of the protein was made following refoldingpanesulfonate, 7.5 mM MnCl2 , 0.1 mM
32P-labeled sub-
strate, and 0.35 mM integrase, unless otherwise specified by including a precipitation step. HTLV-IIG12 IN precipi-
tated upon addition of Buffer C (0.2 M NaCl). The precipi-in the figure legends. A 6.7 mM NaCl concentration is
introduced into the assays due to salt carryover from the tated protein was resuspended in Buffer D (0.5 M NaCl)
to a final concentration of 1 mg/ml. Greater than 95% ofIN storage buffer (Buffer D). Reactions were incubated
at 377 for 60 min and stopped by a further 30-min incuba- the precipitate was HTLV-IIG12 IN, which was highly sta-
ble and soluble in this high-salt environment.tion with 25 mg of proteinase K per reaction in the pres-
ence of 25 mM EDTA and 0.01% SDS at 377. Ten microli- The purified and active HTLV-IIG12 IN fraction refolded
at a concentration of 5 mg/ml was chosen as antigenters of loading dye (95% formamide, 20 mM EDTA, 0.05%
bromophenol blue, 0.5% xylene cyanol) was added fol- for the production of polyclonal antibodies in rabbits.
Western analysis of crude total cell extract (Fig. 1B, laneslowing proteinase K digestion. Reactions were heated
from 3 to 5 min at 957, loaded, separated on 20% denatur- 1) and purified refolded HTLV-IIG12 IN (Fig. 1B, lanes 2)
was examined for reactivity against sera from HTLV-IIG12ing polyacrylamide gel, and subjected to autoradiogra-
phy as previously described (Jonsson et al., 1993). IN-inoculated rabbits. Reactivity of the appropriate-size
protein, 32 kDa, was observed in crude and purified frac-
tions (Fig. 1B, lanes 1 and 2). No cross-reactivity wasSubstrate preparation
noted against HIV-1 IN (Fig. 1B, lane 3). Further, no cross-
Oligonucleotides were purified on 20% denaturing reactivity with higher or lower protein bands occurred
polyacrylamide gels, 32P-labeled at the 5* end with T4 in the immunoanalysis. This suggests the expressed IN
polynucleotide kinase, and hybridized to complementary protein was stable and not affected by endogenous bac-
oligonucleotide strands as previously described (Jons- terial proteases.
son et al., 1993). Unincorporated radioactivity was re-
moved from labeled integration and disintegration sub-
In vitro enzymatic activities of HTLV-IIG12 INstrates with G-25 or G-50 Quick Spin columns (Boeh-
ringer Mannheim, IN). HTLV-IIG12 IN was assayed for 3*-processing, strand
transfer, and disintegration activities with LTR-specific
RESULTS substrates. The assay for 3*-processing uses a blunt-
ended 20-bp DNA substrate that mimics the U5 end of theExpression and purification of the HTLV-IIG12 IN
HTLV-IIG12 LTR (Fig. 2A, Step 1). Strand-transfer activity isprotein
detected by the use of a precleaved duplex DNA sub-
strate (Fig. 2A, Step 2). The blunt-LTR substrate will alsoBL21(DE3) cells harboring the expression vector
pET22HIIg were induced with IPTG to express the HTLV- serve as a strand-transfer substrate following 3*-pro-
cessing. HTLV-IIG12 IN also catalyzes the disintegrationIIG12 IN. Following the induction period, total protein was
extracted under denaturing conditions. Solubilized pro- of a Y-shaped substrate that resembles an integration
intermediate (Fig. 2A, Step 3). Oligonucleotides used intein was subsequently subjected to separation by nickel-
affinity chromatography. Following removal of the major- the synthesis of the substrates in these experiments are
listed in Fig. 2B.ity of the contaminating proteins, HTLV-IIG12 IN was
eluted from the resin by lowering the buffer pH to 4.5. 3*-Processing, strand transfer, and disintegration were
measured over a 10-fold range of protein concentrationThis released HTLV-IIG12 IN in high concentrations into
eight fractions representing 8 column volumes (Fig. 1A, under identical reaction conditions (Fig. 3A). Using the
blunt-end substrate, 3*-processing and strand-transferlanes 4 to 11). As evident from Fig. 1A, high levels of
HTLV-IIG12 IN expression were obtained in E. coli and the activities of the HTLV-IIG12 IN were clearly visible at a
protein concentration of 0.35 pmol/ml (Fig. 3A, lane 7).protein was readily extracted. Binding conditions were
evidently efficient, as seen from the very low traces of This concentration represents a 5:1 ratio of protein to
substrate. At a 2-fold lower concentration of protein (0.17IN in the column flowthrough (Fig. 1A, lane 12). This one-
step affinity purification yielded approximately 70 mg of pmol/ml), 3*-processing activity was only faintly detect-
able (Fig. 3A, lane 6), and strand-transfer products were90–95% homogenous HTLV-IIG12 IN from 1 liter of cells.
Column fractions were pooled and diluted to ascertain not observed. Further dilution in protein concentration
did not reveal any processed products even with longerthe optimal concentration for refolding as measured by
the activity of the HTLV-IIG12 IN enzyme. Each of the re- exposures to X-ray film (Fig. 3A, lanes 2–5). Thus, with
respect to 3*-processing activity, only the higher rangefolded fractions was assayed for integration and disinte-
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FIG. 1. Purification of HTLV-IIG12 IN. (A) HTLV-IIG12 IN protein fractions eluted from the Ni2/ NTA column were separated by 15% SDS–PAGE and
visualized with Coomassie blue staining. Lane numbers are indicated at the top and column fractions are indicated at the bottom. Lanes 2 through
11 represent column fractions 1 to 10 from the pH 4.5 elution step. The major band indicated by the arrow in lanes 3 to 11 corresponds to the
HTLV-IIG12 IN protein of approximately 32 kDa. Lane 12 shows the flowthrough from the column after loading. Lane 1 contains molecular weight
markers (M). (B) Immunoassay of HTLV-IIG12 IN purified from E. coli transformed cells carrying the expression vector pET22HIIg is shown. Crude
HTLV-IIG12 IN (lane 1), refolded HTLV-IIG12 IN (lane 2), and crude HIV-1 IN (lane 3) were separated by 15% SDS–PAGE, transferred on to Nytran
membrane, and incubated with a 1 to 500 dilution of rabbit antisera raised against HTLV-IIG12 IN as described under Materials and Methods. The
positions of molecular weight markers are indicated to the left.
of protein concentration examined produced products. (M. Balakrishnan and C. B. Jonsson, data not shown).
With precleaved substrate, HTLV-IIG12 IN catalyzedHTLV-IIG12 IN also showed dinucleotide cleavage activity
with the HTLV-IIG12 U3 LTR; however, this activity was strand-transfer reactions at IN concentration of 0.17 and
0.35 pmol/ml (Fig. 3A, lanes 13–14). Longer exposuresnotably less than that observed for the U5 LTR substrate
FIG. 2. IN LTR assays and oligonucleotide substrates. (A) Schematic representation of the enzymatic activities mediated by HTLV-IIG12 IN, 3*-
processing (Step 1), strand transfer (Step 2), and disintegration (Step 3) are shown. Integration substrates consist of two complementary 20-
nucleotide oligomers that mimic the terminal U5 or U3 end of the viral LTR (see Fig. 2B). Strand E, which undergoes 3*-processing at the 3* end
is 32P labeled at its 5* end (Step 1). The 3*-processing activity is thus detected by the generation of the 18-nt recessed product. During strand
transfer, the processed LTR serves as a substrate for a one-step transesterification reaction mediated by the HTLV-IIG12 IN (Step 2). Strand transfer
into the target DNA is random, thus generating a spectrum of larger and smaller sized products. The disintegration substrate represents a hypothetical
strand-transfer intermediate (Step 3). This reaction is followed by 32P labeling the 5* end of the C strand. Joining of the 3* end of the C strand to
the B strand results in the formation of a 30-nt product. (B) Oligonucleotide sequences derived from the U5 termini of HTLV-IIG12 and HIV-1 and
used in the synthesis of the substrates are shown. The substrates used to follow 3*-processing activity were synthesized by hybridizing together
the E and A strands. The substrate used to measure strand-transfer activity contained the F and A. The disintegration substrates consisted of the
A, B, C, and D strands. For the A- overhang disintegration substrate the B* strand was used in place of the B strand, while the single-stranded
disintegration substrate lacked the A strand. The conserved -CA residues in the positive strands are underlined. Sequences representing the LTR
region in the B strands are shown in bold.
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FIG. 3. Enzymatic activities of HTLV-IIG12 IN as a function of protein concentration. (A) HTLV-IIG12 IN enzymatic activities were assayed as described
under Materials and Methods using HTLV-II U5 LTR-derived substrates. Enzymatic activity is shown in reactions with increasing concentration of
protein for 3*-processing, lanes 1–7; strand transfer, lanes 8–14; and disintegration, lanes 15–21. The protein concentrations (pmol/ml) are indicated
directly above each lane. Assays were done in 15-ml reaction volumes with a final substrate concentration of 0.07 pmol/ml. Reactions of substrate
without protein are shown in the first lane of each reaction set. The 18-nucleotide species in lanes 15–21 is due to formation of secondary structures
during substrate synthesis and has been observed before (29). (B) 3*-Processing and strand-transfer activities using increasing concentrations of
HTLV-IIG12 IN were examined with the blunt-ended HTLV-II U5 LTR substrate. Enzyme activity in presence of increasing concentrations of protein
is shown in lanes 2–8. Protein concentrations are indicated directly above each lane. Substrate concentration used in these assays was 0.07 pmol/
ml. Reaction with substrate in the absence of protein is represented in lane 1. In A and B, reactions were incubated at 377 for 60 min and terminated
with proteinase K treatment for 30 min at 377.
showed reactions containing 0.14 pmol/ml HTLV-IIG12 IN, twofold at 3.46 and 6.9 pmol/ml IN concentration (Fig.
3B, lanes 7 and 8). Strand-transfer activity decreasedactive for strand transfer (Fig. 3A, lane 12). This repre-
sents a 2:1 ratio of substrate to protein concentration in substantially as protein concentrations were increased
above 1.7 pmol/ml (Fig. 3B, lanes 7 and 8). At 6.9 pmol/the assay. No activity was observed in reactions con-
taining 0.035–0.10 pmol/ml of IN (Fig. 3A, lanes 9–11). ml, strand-transfer products were undetectable. Strand-
transfer activity with the 3*-processed substrate showedStrand-transfer activity required approximately 2-fold less
protein compared to 3*-processing reaction. similar inhibitory effects at the higher IN concentrations
of 3.46 and 6.9 pmol/ml (data not shown). A time courseIn contrast to 3*-processing and strand-transfer
assays, the disintegration reaction yielded a 30-nucleo- measured enzymatic activity for HTLV-IIG12 IN over a pe-
riod of 60 min to compare the kinetics of 3*-processing,tide product at the lowest HTLV-IIG12 IN concentration
examined, 0.035 pmol/ml (Fig. 3A, lane 16). This concen- strand transfer, and disintegration (data not shown). With
the blunt-LTR substrate, the 3*-processed product ap-tration of IN reflects a 1:2 ratio of protein to substrate in
the assay. The level of activity increased with increasing peared within 2 min of incubation followed by strand-
transfer products by the end of 5 min. Products fromprotein concentration (Fig. 3A, lanes 16 to 21). Disintegra-
tion activity required approximately 10-fold less HTLV- HTLV-IIG12 IN-catalyzed strand-transfer and disintegra-
tion reactions were observed in less than 1 min. As ob-IIG12 IN protein compared to the 3*-processing and 5-fold
less compared to strand transfer. The IN concentrations served in protein to substrate titration, the time course
highlights the kinetic efficiency of strand transfer as op-needed to observe 3*-processing, strand transfer, and
disintegration activities thus showed distinct variation. posed to the relatively slower 3*-processing.
In all enzymatic assays, HTLV-IIG12 IN activity was in-
hibited at protein concentrations above 2.0 pmol/ml (Fig. Ionic strength, metal ion, and temperature
3B, and data not shown). In Fig. 3B, the blunt-ended requirements
integration substrate serves to show both 3*-processing
and strand-transfer activities at protein concentrations The effect of increasing sodium chloride concentration
and metal ion requirement was examined for the in vitroranging from 0.34 pmol/ml (Fig. 3B, lane 2) to 6.93 pmol/ml
(Fig. 3B, lane 8). 3*-Processing activity fell approximately integration and disintegration reactions catalyzed by
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FIG. 4. Salt and metal requirements of HTLV-IIG12 IN enzymatic activities. (A) The optimal NaCl concentration for 3*-processing (lanes 1–9), strand-
transfer (lanes 10–18), and disintegration (lanes 19–27) activities for HTLV-IIG12 IN were investigated. The NaCl concentrations are indicated directly
above each lane. Reactions of substrate without protein are shown in the first lane of each reaction set (lanes 1, 10, and 19). Standard reaction
conditions that contain 6.7 mM NaCl and which were used throughout the study are represented in the second lane of each reaction set (lanes 2,
11, and 20). Subsequent lanes show reactions conducted with increasing NaCl concentrations of 8 mM (3, 12, and 21), 9 mM (lanes 4, 13, and 22),
10 mM (lanes 5, 14, and 23), 50 mM (lanes 6, 15, and 24), 100 mM (lanes 7, 16, and 25), 250 mM (lanes 8, 17, and 26), and 500 mM (lanes 9, 18,
and 27). (B) Metal requirements for optimal 3*-processing (lanes 1–7), strand-transfer (lanes 8–14), and disintegration (lanes 15–21) activities were
examined for HTLV-IIG12 IN. Reactions containing radiolabeled substrate in the absence of protein are represented in the first lane of each reaction
set (lanes 1, 8, and 15). Reactions done under standard buffer conditions with 7.5 mM Mn2/ are represented in the second lane of each reaction
set (lanes 2, 9, and 16). Lanes 3–7, 10–14, and 17–21 represent reactions where the 7.5 mM Mn2/ was substituted with 10 mM Mn2/ (lanes 3,
10, and 17), 5 mM Mn2/ and 5 mM Mg2/ (lanes 4, 11, and 18), 10 mM Mg2/ (lanes 5, 12, and 19), 10 mM Zn2/ (lanes 6, 13, and 20), and 10 mM
Co2/ (lanes 7, 14, and 21). In both A and B substrate for 3*-processing is represented by the 20-nt band and the 3*-processed product is detected
as the shortened 18-nt band. The precleaved substrate used to detect strand-transfer activity is represented by the 18-nt band, while the strand-
transfer products are detected by the presence of the slower migrating bands above the substrate bands. The disintegration substrate is represented
by the 16-nt band, while the disintegration product is represented by the 30-nt band. Assays were performed in 15-ml reaction volume with 0.1 mM
labeled substrate and 0.35 mM IN.
HTLV-IIG12 IN. Enzymatic activity was compared under (Fig. 4A, lanes 26–27). However, of the three HTLV-IIG12
IN activities, disintegration activity proved the most sub-identical conditions for each of the three substrates in
stantial in a higher salt environment.the presence of increasing salt concentrations (Fig. 4A).
The 6.7 mM NaCl at the lower end of the salt titration Integration and disintegration activities of HTLV-IIG12
represents carryover from the IN storage buffer (see Ma- IN were examined in the presence of four different diva-
terials and Methods). With the blunt-LTR substrate, 3*- lent cations, namely, Mn2/, Mg2/, Zn2/, and Co2/ (Fig.
processed product was detectable through 100 mM NaCl 4B). Integration reactions of IN have an absolute require-
concentration (Fig. 4A, lanes 2–7). The level of 18-nucleo- ment for magnesium or manganese. To date, disintegra-
tide product decreased at 100 mM NaCl (Fig. 4A, lane tion activity has only been measured with Mn2/. HTLV-
7). Higher salt concentrations of 250 and 500 mM NaCl IIG12 IN catalyzed both 3*-processing and strand-transfer
inhibited 3*-processing completely (Fig. 4A, lanes 8 and activities in the presence of either 10 mM MnCl2 (Fig.
9). The assay for strand-transfer activity tolerated salt 4B, lanes 3 and 10) or 10 mM MgCl2 (Fig. 4B, lanes 5
concentrations through 50 mM (Fig. 4A, lanes 11–15). and 12), but no enzyme activity was observed in the
Strand-transfer activity was notably reduced at 100 mM presence of ZnSO4 (Fig. 4B, lanes 6 and 13) or CoCl2
NaCl concentrations (Fig. 4A, lane 16). At salt concentra- (Fig. 4B, lanes 7 and 14). This closely compares with the
tions above 100 mM, strand-transfer products were ab- standard buffer conditions used herein (MnCl2 at 7.5 mM,
sent (Fig. 4A, lanes 17 and 18). We observed equivalent Fig. 4B, lanes 2 and 9). While the cleavage step was
levels of disintegration activity from 6 to 100 mM NaCl catalyzed equally well in the presence of either of the
cations (Fig. 4B, lanes 3 and 5), strand-transfer activity(Fig. 4A, lanes 19–25), but not at 250 and 500 mM NaCl
AID VY 7865 / 6a15$$$$61 04-02-96 22:42:49 vira AP: Virology
83HUMAN T-CELL LEUKEMIA VIRUS-II INTEGRASE
showed a distinct preference for Mn2/ (Fig. 4B, lanes 10 overhang Y substrate, Fig. 6A) (Chow et al., 1992). In
contrast, the splicing activity with the M-MuLV IN showsand 12). Disintegration activity showed a trend similar to
3*-processing, working equally well in MnCl2 or MgCl2 a strict requirement for the LTR portion of the disintegra-
tion substrate and only catalyzes reactions with at leastenvironment (Fig. 4B, lanes 17–19); however, no enzyme
activity was observed in the presence of ZnSO4 (Fig. 17 nucleotides of the LTR in a single-stranded form (Don-
zella et al., 1993). The molecular basis for these differ-4B, lane 20) or CoCl2 (Fig. 4B, lane 21). An interesting
observation in these studies was the effect of mixing ences is unknown. It was of interest to compare these
activities with HTLV-IIG12 IN’s activities to define whichMnCl2 and MgCl2 in the HTLV-IIG12 IN reactions. 3*-Pro-
cessing was catalyzed as efficiently in the presence of type of enzymatic activity it would have, and perhaps to
lend insight into whether the HTLV-IIG12 IN was similarMnCl2 or MgCl2 or in their mixed presence (Fig. 4B, lanes
3–5), while strand transfer (Fig. 4B, lanes 10–12) and catalytically to HIV-1 IN or M-MuLV IN.
Two prototype single-stranded disintegration sub-disintegration (Fig. 4B, lanes 17–19) were reduced. Fi-
nally, no significant difference in the final levels of reac- strates were examined for HTLV-IIG12 IN activity (Fig. 6B).
The standard Y substrate, the single-stranded, and thetion products were noted at 30 or 377 (M. Balakrishnan
and C. B. Jonsson, data not shown). A- overhang Y substrates are identical in sequence in
the C and D regions. The three disintegration substrates
Catalysis with HIV-1 LTR substrates differ only in the viral LTR. Activity with the standard
double-stranded disintegration substrate was measured
IVDAs are quite often co-infected with both HTLV-II
for comparison (Fig. 6B, lane 2). The A- overhang Y sub-
and HIV-1, and the viruses are capable of interaction in
strate contained a shortened B strand (B*) having a single
vivo (de-The and Bomford, 1993; Hall et al., 1992; Lee et
nucleotide instead of the LTR arm (Fig. 6A). Enzymatic
al., 1989; Wang et al., 1993). Whether these two retrovi-
activity of HTLV-IIG12 IN with the A- overhang Y substrateruses could integrate one another’s genomes is un-
was not observed even with longer exposures in several
known. To gain further insight, we measured HTLV-IIG12 attempts (Fig. 6B, lane 4). The single-stranded Y sub-
IN activity for 3*-processing, strand transfer, and disinte-
strate contained 19 nucleotides of the HTLV-IIG12 LTRgration using HIV-1 U5 LTR integration and disintegration
in the single-stranded form, while the remainder of the
substrates.
substrate was double-stranded (Fig. 6A). The 30-nucleo-
HTLV-IIG12 IN showed efficient cleavage of the blunt tide disintegration product was not detected with the
U5 LTR substrate from HIV-1 (Fig. 5A, lane 4). Strand-
single-stranded Y substrate (Fig. 6B, lane 6). It was sur-
transfer activity was also observed with the precleaved
prising that no activity was detected with either of these
HIV U5 LTR substrates, though the levels of activity were
disintegration substrates. This suggests that the splicing
lower than that observed with the HTLV-IIG12 LTR (com- activity may not be common to all retroviral integrases.
pare Fig. 5A, lane 8 to lane 6). Interestingly, the pattern
of strand-transfer activity observed with the HTLV-IIG12
DISCUSSIONIN on the HIV LTR appeared identical to that observed
with the HIV-1 IN on its own LTR (M. Balakrishnan and
HTLV-IIG12 IN expressed in and purified from E. coliC. B. Jonsson, unpublished results). The HTLV-IIG12 and was highly active, catalyzing integration and disintegra-
HIV-1 disintegration substrates differ in sequences only
tion activities characteristic of this class of proteins.
in their LTR arms and are identical in the target. HTLV-
Unique to this characterization study were protein titra-
IIG12 IN catalyzed disintegration reaction with the HIV-1 tions that defined a critical concentration of HTLV-IIG12Y substrate, generating the 30-nt product (Fig. 5B, lane
IN required to bring about the different enzymatic activi-
4). Activity on the HTLV-IIG12 Y substrate is shown in Fig. ties, 3*-processing, strand transfer, and disintegration.
5B, lane 2. Preference for the HTLV-IIG12 substrates over We estimate that while 3*-processing required a 5:1 ratio
the HIV-1 substrates by HTLV-IIG12 IN was clearly more of protein:substrate concentration in the assay, strand
pronounced with the integration substrates than with the
transfer, in the presence of the precleaved LTR, required
disintegration substrates (compare Figs. 5A and 5B).
only a 2:1 ratio to generate integration products. Thus,
Therefore, sequence played a more crucial role in sub-
the initial step of LTR processing required approximately
strate recognition for the integration activity of HTLV-IIG12 twice the amount of protein than was required to catalyze
IN than for disintegration activity.
strand transfer. Disintegration was clearly the most rap-
idly catalyzed reaction requiring 10- and 5-fold less pro-Splicing activity of HTLV-IIG12 IN tein compared to the 3*-processing and strand-transfer
activities of the HTLV-IIG12 IN, respectively.The splicing activity of HIV-1 IN demonstrates a re-
markable enzymatic flexibility marked by its ability to cat- Our studies show the HTLV-IIG12 IN to be fairly tolerant
to and stable at moderate salt concentrations (100 mMalyze reactions with single-stranded disintegration sub-
strates (single-stranded Y substrate, Fig. 6A) and with a NaCl), and optimal activity could be attained at as low
as 6.7 mM NaCl. This was comparable to HIV-1 IN whichsingle nucleotide overhang disintegration substrate (A-
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FIG. 5. Activity of HTLV-IIG12 IN with HIV-1 substrates. HTLV-IIG12 IN was assayed using HTLV-IIG12 and HIV-1 U5 LTR-derived substrates. (A)
3*-Processing (lanes 1 – 4) and strand-transfer (lanes 5– 8) activities are presented for HTLV-IIG12 IN. 3*-Processing activities of HTLV-IIG12 IN with
the HTLV-II LTR (lane 2, 18-nt product) and HIV-1 LTR (lane 4, 19-nt product) are shown. Products are indicated by asterisk. Substrate assays
without the addition of IN are shown in lanes 1 and 3. Strand-transfer reactions (lanes 5 – 8) with HTLV-IIG12 LTR (lane 5 and 6) and HIV-1 LTR
(lane 7 and 8) are shown for HTLV-IIG12 IN. Strand-transfer products are represented by the slower migrating bands (lanes 6 and 8). Substrate
reactions without IN are shown for comparison in lanes 5 and 6. (B) Disintegration substrates (16 nt) from HTLV-IIG12 (lanes 1 and 2) and HIV-1
(lanes 3 and 4) are represented by the 16-nt bands. Even-numbered lanes show substrate reactions in the presence of HTLV-IIG12 IN protein.
Disintegration products are indicated by the presence of a 30-nt band (lanes 2 and 4). Odd-numbered lanes show substrate reactions in the
absence of HTLV-IIG12 IN protein. In both A and B assays were performed as described under Materials and Methods with 0.1 mM labeled
substrate and 0.35 mM HTLV-IIG12 IN.
is fully active at 100 mM NaCl (Drelich et al., 1992). Com- The role of manganese ion in controlling the proposed
stereochemistry of the polynucleotidyl transfer during in-paring other INs, AMV IN has a higher salt requirement,
showing maximal activity at 145 mM NaCl (Vora et al., tegration is not understood at present. Precedents from
studies of phosphoryl and nucleotidyl transfer reactions1990), while M-MuLV and visna virus INs are progres-
sively inhibited by 25 to 100 mM NaCl (Jonsson et al., would suggest that the manganese ion has an important
role in acceleration of the Sn2 reaction pathway by bind-1993) and 50 to 150 mM NaCl (Katzman and Sudol, 1994),
respectively. HTLV-IIG12 IN catalyzed 3*-processing and ing the entering group or the phosphoryl group (Steitz
and Steitz, 1993).disintegration with equal efficiency in the presence of
either Mn2/ or Mg2/. Strand-transfer activity was also HTLV-IIG12 IN did not have a strict specificity for its
own LTR, and it recognized blunt-ended and processedmediated in presence of either of the divalent cations,
although there was a definite preference for Mn2/. Inter- LTRs from HIV-1. Certain retroviral integrases have been
reported to act on heterologous LTR substrates, althoughestingly, adding both Mn2/ and Mg2/ in the reaction envi-
ronment lowered strand-transfer and disintegration activ- no obvious recognition sequences among these LTRs
have been identified (Bushman and Craigie, 1990; Katz-ities, but not 3*-processing. Studies on the AMV IN (Vora
et al., 1990; Fitzgerald et al., 1992), ASLV IN (Katz et al., man et al., 1989; Katzman and Sudol, 1994; Leavitt et al.,
1992; Sherman et al., 1992). Our studies showed that1990; Katzman et al., 1991), HIV-1 IN (Vincent et al., 1993;
Engelman and Craigie, 1995), and HIV-2 IN (Vink et al., HTLV-IIG12 IN also possessed this flexibility, recognizing
both HTLV-II and HIV-1 U5 LTR substrates. Difference in1991) have also reported various levels of integration
activity with Mg2/. In contrast, INs from M-MuLV (Craigie sequence requirements for disintegration has also been
observed for M-MuLV IN (Donzella et al., 1993; Jonssonet al., 1990; Jonsson et al., 1993), FIV (Vink et al., 1994),
visna virus (Katzman and Sudol, 1994), and human foamy and Roth, 1993). Of interest, HTLV-IIG12 IN did not catalyze
reactions with the disintegration ‘‘splicing’’ substrates. Tovirus (Pahl and Fugel, 1993) exhibit strong preference for
Mn2/ with no detectable activity in the presence of Mg2/. date, only HIV-1 IN demonstrates this enzymatic activity
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LTR substrate recognition by IN, LTR–IN complex forma-
tion, and processing mechanisms remain to be an-
swered.
ACKNOWLEDGMENT
We thank Shawn Dark for his expert technical assistance.
REFERENCES
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation
of microgram quantities of protein utilizing the principle of protein-
dye binding. Anal. Biochem. 72, 248–254.
Brown, P. O. (1990). Integration of retroviral DNA. Curr. Top. Microbiol.
Immunol. 157, 19–48.
Brown, P. O., Bowerman, B., Varmus, H. E., and Bishop, J. M. (1989).
Retroviral integration: Structure of the initial covalent product and its
precursor, and a role for the viral IN protein. Proc. Natl. Acad. Sci.
USA 86, 2525–2529.
Bushman, F. D., and Craigie, R. (1990). Sequence requirements for
integration of Moloney murine leukemia virus DNA in vitro. J. Virol.
64, 5645–5648.
Chen, I. S. Y., McLaughlin, J., Gasson, J. C., Clark, S. C., and Golde,
D. W. (1983). Molecular characterization of genome of a novel human
FIG. 6. Disintegration reactions catalyzed by HTLV-IIG12 IN using T-cell leukemia virus. Nature 305, 502–505.
standard and modified disintegration substrates. (A) Schematic repre- Chow, S. A., Vincent, K. A., Ellison, V., and Brown, P. O. (1992). Reversal
sentation of the three different disintegration substrates used in these of integration and DNA splicing mediated by integrase of human
assays. The standard Y substrate is represented in the uppermost immunodeficiency virus. Science 255, 723–726.
schematic. The single-stranded Y substrate (center) was generated by Craigie, R., Fujiwara, T., and Bushman, F. (1990). The IN protein of
omission of the A strand during hybridization. The A- overhang Y sub- Moloney murine leukemia virus processes the viral DNA ends and
strate (bottom) was synthesized by omitting the A strand and using the accomplishes their integration in vitro. Cell 62, 829–837.
shortened B* strand. (B) Enzymatic assays using the standard Y sub- de-The, G., and Bomford, R. (1993). An HTLV-I vaccine: Why, how, for
strate (lanes 1 and 2), A- overhang Y substrate (lanes 3 and 4), and whom? AIDS Res. Hum. Retroviruses 9, 381–386.
the single-stranded Y substrate (lanes 5 and 6) are shown for HTLV- Donzella, G. A., Jonsson, C. B., and Roth, M. J. (1993). Influence of
IIG12 IN. Even-numbered lanes show reactions in the presence of HTLV- substrate structure on disintegration by Moloney murine leukemia
IIG12 IN protein. Odd-numbered lanes show reactions in the absence virus integrase. J. Virol. 67, 7077–7087.
of HTLV-IIG12 IN protein. Substrates are represented by the 16-nt band Drelich, M., Wilhelm, R., and Mous, J. (1992). Identification of amino
and products are detected by the presence of the 30-nt band. Disinte- acid residues critical for endonuclease and integration activities of
gration reactions were performed under identical conditions with each HIV-1 IN protein in vitro. Virology 188, 459–468.
substrate as described under Materials and Methods in the presence Ellison, V., Gerton, J., Vincent, K. A., and Brown, P. O. (1995). An essential
of 0.1 mM substrate and 0.35 mM IN. interaction between distinct domains of HIV-1 integrase mediates
assembly of the active multimer. J. Biol. Chem 270(7), 3320–3326.
Engelman, A., and Craigie, R. (1995). Efficient magnesium-dependent
human immunodeficiency virus type 1 integrase activity. J. Virol. 69,on a single A- overhang disintegration substrate (Chow
5908–5911.
et al., 1992). M-MuLV IN requires 17 nucleotides in the Engelman, A., Mizuuchi, K., and Craigie, R. (1991). HIV-1 DNA integra-
single-stranded region to catalyze this splicing activity tion: Mechanism of viral DNA cleavage and DNA strand transfer.
Cell 67, 1211–1221.(Donzella et al., 1993). Clearly, additional biochemical
Fitzgerald, M. L., Vora, A. C., Zeh, W. G., and Grandgenett, D. P. (1992).analysis of the splicing activity is needed to understand
Concerted integration of viral DNA termini by purified avian myelo-the observed differences.
blastosis virus integrase. J. Virol. 66, 6257–6263.
In the presence of the viral DNA genome, the preinte- Grandgenett, D. P., and Mumm, S. R. (1990). Unraveling retrovirus inte-
gration complex forms a highly organized structure gration. Cell 60, 3–4.
Hall, W. W., Takahashi, H., Liu, C., Kaplan, M. H., Scheewind, O., Ijichi,(Brown et al., 1989) via interaction with the IN protomers
S., Nagashima, K., and Gallo, R. C. (1992). Multiple isolates and(Ellison et al., 1995). Hypothetically, the conformation or
characteristics of human T-cell leukemia virus type II. J. Virol. 66,Km of this initial IN–viral DNA complex may be more 2456–2463.
stringent for initiating 3*-processing compared to strand- Hjelle, B., Mills, R., Swenson, S., Mertz, G., Key, C., and Allen, S. (1991).
transfer activity. We speculate that while strand-transfer Incidence of hairy cell leukemia, mycosis fungoides, and chronic
lymphocytic leukemia in first known HTLV-II endemic population. J.activity may not require the entire preintegration nucleo-
Infect. Dis. 163, 435–440.protein complex, once formed, the complex may be main-
Jonsson, C. B., and Roth, M. J. (1993). Role of the His–Cys finger oftained until the integration occurs. To what extent the
the Moloney murine leukemia virus integrase protein in integration
LTR sequence contributes to complex formation in the and disintegration. J. Virol. 67, 5562–5571.
3*-processing and strand-transfer activities by IN is cer- Jonsson, C. B., Donzella, G. A., and Roth, M. J. (1993). Characterization of
the forward and reverse integration reactions of the Moloney murinetainly of interest. Clearly, important questions regarding
AID VY 7865 / 6a15$$$$61 04-02-96 22:42:49 vira AP: Virology
86 BALAKRISHNAN, ZASTROW, AND JONSSON
leukemia virus integrase protein purified from Escherichia coli. J. human T-cell lymphotrophic virus type II (HTLV-II) isolate: Identifica-
tion of a variant HTLV-II subtype b from a Guaymi Indian. J. Virol. 67,Biol. Chem. 268, 1462–1469.
Kalyanaraman, V. S., Sarngadharan, M. G., Robert-Guroff, M., Miyoshi, 4659–4664.
Roth, M. J., Schwartzberg, P. L., and Goff, S. P. (1989). Structure of theI., Blayney, D., Golde, D., and Gallo, R. (1982). A new subtype of
human T-cell leukemia virus (HTLV-II) associated with a T-cell variant termini of DNA intermediates in the integration of retroviral DNA:
Dependence on IN function and terminal DNA sequence. Cell 58,of hairy cell leukemia. Science 218, 571–573.
Kaplan, M. H., Hall, W. W., Susin, M., Pawha, S., Salahuddin, S. Z., 47–54.
Sherman, P. A., Dickson, M. L., and Fyfe, J. A. (1992). Human immunode-Heilman, C., Petten, J., Coronesi, M., Farber, B. F., and Smith, S.
(1991). Syndrome of severe skin disease, ecosinophilia, and derma- ficiency virus type 1 integration protein: DNA sequence requirements
for cleavage and joining requirements. J. Virol. 66, 3593–3601.topathy in patients with HTLV-II complicating human immunodefi-
ciency virus infection. Am. J. Med. 91, 300–309. Steitz, T. A., and Steitz, J. A. (1993). A general two-metal-ion mechanism
for catalytic RNA. Proc. Natl. Acad. Sci. USA 90, 6498–6502.Katz, R. A., Merkel, G., Kulkosky, J., Leis, J., and Skalka, A. M. (1990).
The avian retroviral IN protein is both necessary and sufficient for Studier, F. W., and Moffat, B. A. (1986). Use of bacteriophage T7 RNA
polymerase to direct selective high-level expression of cloned genes.integrative recombination in vitro. Cell 63, 87–95.
Katzman, M., and Sudol, M. (1994). In vitro activities of purified visna J. Mol. Biol. 189, 113–130.
Varmus, H., and Swanstrom, R. (1984). Replication of retroviruses. Invirus integrase. J. Virol. 68, 3558–3569.
Katzman, M., Katz, R. A., Skalka, A. M., and Leis, J. (1989). The avian ‘‘RNA Tumor Viruses’’ (R. Weiss, N. Teich, H. Varmus, and J. Coffin,
Eds.), pp. 369–512. Cold Spring Harbor Laboratory, New York.retroviral integration protein cleaves the terminal sequences of linear
viral DNA at the in vivo sites of integration. J. Virol. 63, 5319–5327. Vincent, K. A., Ellison, V., Chow, S. A., and Brown, P. O. (1993). Charac-
terization of human immunodeficiency virus type 1 integrase ex-Katzman, M., Mack, J. P. G., Skalka, A. M., and Leis, J. (1991). A covalent
complex between retroviral integrase and nicked substrate DNA. pressed in Escherichia coli and analysis of variants with amino-
terminal mutations. J. Virol. 67, 425–437.Proc. Natl. Acad. Sci. USA 88, 4695–4699.
Leavitt, A. D., Rose, R. B., and Varmus, H. E. (1992). Both substrate and Vink, C., van der Linden, K. H., and Plasterk, R. H. A. (1994). Activities
of the feline immunodeficiency virus integrase protein produced intarget oligonucleotide sequences affect in vitro integration mediated
by human immunodeficiency virus Type 1 integrase protein produced Escherichia coli. J. Virol. 68, 1468–1474.
Vink, C., van Gent, D. C., Elgersma, Y., and Plasterk, R. H. A. (1991).in Saccharomyces cerevisiae. J. Virol. 66, 2359–2368.
Lee, H., Swanson, P., Shorty, V. S., Zack, J. A., Rosenblatt, J. D., and Human immunodeficiency virus integrase protein requires a subter-
minal position of its viral DNA recognition sequence for efficientChen, I. S. Y. (1989). High rate of HTLV-II infection in seropositive IV
drug abusers in New Orleans. Science 244, 471–475. cleavage. J. Virol. 65, 4636–4644.
Vogelstein, B., and Gillespie, D. (1979). Preparative and analytical purifi-Levine, P. H., Jacobson, S., Elliott, R., Cavallero, A., Colclough, G., Dorry,
C., Stephenson, C., Knigge, R. M., Drummond, J., Nishimura, M., Tay- cation of DNA from agarose. Proc. Natl. Acad. Sci. USA 76, 615–
619.lor, M. E., Wiktor, S., and Shaw, G. (1993). HTLV-II infection in Florida
Indians. AIDS Res. Human Retroviruses 9, 123–127. Vora, A. C., Fitzgerald, M. L., and Grandgenett, D. P. (1990). Removal
of 3*-OH-terminal nucleotides from blunt-ended long terminal repeatPage, J. B., Lai, S., Chitwod, D. D., Klimas, N. G., Smith, P. C., and
Fletcher, M. A. (1990). HTLV-I/II seropositivity and death from AIDS termini by the avian retrovirus integration protein. J. Virol. 64, 5656–
5659.among HIV-I seropositive intravenous drug abusers. Lancet 335,
1439–1441. Wang, B., Agadjanyan, M. G., Srikantan, V., Ugen, K. E., Hall, W. W.,
Kaplan, M. H., Dang, K., Williams, W. V., and Weiner, D. B. (1993).Pahl, A., and Fugel, R. M. (1993). Endonucleolytic cleavages and DNA-
joining activities of the integration protein of human foamy virus. J. Molecular cloning, expression, and biological characterization of an
HTLV-II envelope glycoprotein: HIV-1 expression is permissive forVirol. 67, 5426–5434.
Pardi, D., Switzer, W. M., Hadlock, K. G., Kaplan, J. E., Lal, R. B., and HTLV-II induced cell fusion. AIDS Res. Hum. Retroviruses 9, 849–
869.Folks, T. M. (1993). Complete nucleotide sequence of an Amerindian
AID VY 7865 / 6a15$$$$61 04-02-96 22:42:49 vira AP: Virology
